| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8528501 | Clinical Therapeutics | 2017 | 12 Pages |
Abstract
In this observational study, patients initiating canagliflozin had greater reduction in HbA1c and longer persistence with medication than did patients who initiated sitagliptin, over a 9-month period. Better understanding of antihyperglycemic treatment, HbA1c results, and differences among patients in demographic/clinical characteristics as well as persistence with treatment will inform optimal diabetes treatment choice in routine practice.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Sarah PhD, Richard MD, Stephanie MPH, Wing PharmD, MPH,